Lia Gore, MD

Professional Titles

• Section Head, Pediatric Hematology/Oncology/BMT
• Ergen Family Chair in Pediatric Oncology
• Co-Director, Developmental Therapeutics Program, University of Colorado Cancer Center

Recognitions

• New Inventor of the Year, University of Colorado (2007)
  
• 5280 Top Docs, 5280 Magazine (2016)
• 5280 Top Docs, 5280 Magazine (2015)
• 5280 Top Docs, 5280 Magazine (2014)
• 5280 Top Docs, 5280 Magazine (2012)
• America's Top Oncologists, Consumers Research Council of America (2007)
• America's Top Oncologists, Consumers Research Council of America (2008)
• America's Top Oncologists, Consumers Research Council of America (2009)
• America's Top Oncologists, Consumers Research Council of America (2010)
• America's Top Oncologists, Consumers Research Council of America (2011)
• America's Top Oncologists, Consumers Research Council of America (2012)
• America's Top Oncologists, Consumers Research Council of America (2013)
• America's Top Oncologists, Consumers Research Council of America (2014)
• America's Top Oncologists, Consumers Research Council of America (2015)
• America's Top Oncologists, Consumers Research Council of America (2016)
• Distinguished Achievement Award, Carleton College (2012)
• 5280 Top Docs, 5280 Magazine (2017)
• 5280 Top Docs, 5280 Magazine (2018)
• 5280 Top Docs, 5280 Magazine (2019)
• 5280 Top Docs, 5280 Magazine (2020)
• 5280 Top Docs, 5280 Magazine (2021)
• 5280 Top Docs, 5280 Magazine (2022)
• 5280 Top Docs, 5280 Magazine (2023)

Research Interests

I am interested in Phase I clinical trials and Clinical-Translational Research in novel cancer treatments, with a particular emphasis on leukemias, sarcomas, and pediatric brain tumors.

Publications

• Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendran A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L, on behalf of the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2013 Feb;60(2):230-236. PubMed PMID: 23024067
• Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatr Blood Cancer. 2012 Dec 15;59(7):1252-8. PubMed PMID: 22887831
• Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2012 Oct;30(5):1942-9. PubMed PMID: 21931969
• Macy ME, DeRyckere D, Gore L. Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents. Invest New Drugs. 2012 Apr;30(2):468-79. PubMed PMID: 21046425
• Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Wen W. Ma, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh L-T, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 18:21 6040-6048; Published OnlineFirst September 7, 2012; doi:10.1158/1078-0432.CCR-12-1652.
• Gore L, Alvaro F, Arndt C, Barnette P, Cooper T, Jones M, Martin L, Mechinaud F, Narendran A, Mshinchi JS, Arceci RJ, Boklan J, Tarasoff P, Tcheng W. Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine as an Epigenetic Priming Agent when Combined with Induction Chemotherapy in Pediatric Patients (PTS) with Newly Dianosed Acute Myelogenous Leukemia (AML). Presented at the Annual Meeting of the American Society of Hematology. December 2012. Atlanta GA.
• Norris R, Shusterman S, Gore L, Macy M, Muscal J, Fox E, Mosse Y, Berkowitz N, Buchbinder A, Bagatell R. Phase I trial of Polyethylene Glycol (PEG) Conjugated SN38 in Patients (Pts) with Recurrent or Refractory Neuroblastoma (NB) and Other Solid Tumors. Oral Presentation at the Advances in Neuroblastoma Research meetings. June 2012. Toronto, Canada.
• Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb;31(1):115-25. PubMed PMID: 22415798
• Cooper T, Chang W, Gaynon P, DuBois S, Neville K, Thomson B, Gore L, Brown P, Gammon G, August K, Brown P. A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances of Childhood Leukemia and Lymphoma (TACL) Study. Presented at the Annual Meeting of the American Society of Hematology. December 2012. Atlanta GA.
• Salzer W, Jones T, Dreyer ZE, Gore L, Winick N, Sung L, Raetz E, Devidas M, Carroll W, Hunger SP, Hilden J, Brown P. Decreased Induction Morbidity and Mortality with Changes to Induction Chemotherapy in Infants wtih Acute Lymphoblastic Leukemia Enrolled on Children's Oncology Group (COG) Trial AALL0631. Presented at the Annual Meeting of the American Society of Hematology meeting. December 2012. Atlanta GA.
• Jimena A, Bowles D, Diamond J, Lam E, Messersmith WA, Weekes CD, Leong S, Gore L, Lieu C, Freas E, Chen R, Wilhelm F, Eckhardt SG. Phase I Study of Oral Rigosertib in Patients with Advanced Solid Tumors. Poster Discussion Presentation at the Annual Meeting of the American Society of Clinical Oncology. June 2012. Chicago IL.
• Hijiya N, Shaevitz S, Kearns P, Gore L, Stork L, Bertrand Y, Bradley-Garelik MB, Zwann CM. A phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous leukemia (CML-CP) or Philadelphia Chromosome positive (Ph+) Leukemias Resistant or Intolerant to Imatinib. Presented at the Annual meeting of the American Society of Clinical Oncology. June 2012. Chicago IL.
• Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald T, Smith AA, Etzl MM, Narendran A, Gore L, Trippett TM, DiRenzo J, Foreman NK, Dunkel IJ. A phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high grade astrocytomas; a preliminary report from POETIC. Oral Presentation at the International Society of Pediatric NeuroOncology. June 2012. Toronto, Canada.
• Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27;121(26):5154-7. PubMed PMID: 23678006
• Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K, Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. Clin Cancer Res. 2013 Jul 1;19(13):3649-58. PubMed PMID: 23659969
• Hoffman LM, Gore L, Maloney KW. Pulmonary Presentation of Relapsed Acute Myeloid Leukemia. J Pediatr Hematol Oncol. 2013 Apr 24. [Epub ahead of print] PubMed PMID: 23619108
• Cohen KJ, Gibbs IC, Fisher PG, Hayashi RJ, Macy ME, Gore L. A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol. 2013 Jun;15(6):783-7. PubMed PMID: 23460318
• Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PubMed PMID: 23434733
• Pollyea DA, Gore L, Gutman JA, Eckhardt SG, Hagelstrom N, Coutre S, Byrd J. 2013. A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Oral Presentation at the Therapeutically Applicable Targets (TAT) Meeting, Paris, France, March 2013.
• Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success?. Lancet Oncol. 2013 Feb;14(2):e70-8. PubMed PMID: 23369685
• Pearson ADJ, Frappaz D, Marshall L, Angelini P, Gatz S, DuBois S, Gore L, Doz F, Iannone R, Geschwindt R, Georger B. A Phase I Study of Ridaforolimus (MK-8669) in Pediatric Patients with Advanced Solid Tumors. Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, 31: 116443.
• Frappaz D, McGregor LM, Pearson ADJ, Gore L, DuBois SG, Aerts I, Iannone R, Geschwindt R, VanSchanke A, Wang R, Geoerger B. 2013. A phase I study of the anti-insulin like growth factor type I receptor (IGF-1R) antibody dalotuzumab in pediatric patients with advanced solid tumors. Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, 31: 115631.
• Neville K, Gore L, Mauz-Körholz C, Rosolen A, Landman-Parker J, Sanchez de Toledo J, Beishuizen A, Franklin ARK, Fasanmade A, Wang J, Huebner D, Locatelli F, Phase 1/2 study of brentuximab vedotin in pediatric patients (pts) with relapsed or refractory systemic anaplastic large-cell lymphoma (sALCL) or Hodgkin lymphoma (HL): Interim phase 1 safety data. Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, 31: 112461.
• Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald T, Smith AA, Etzl MM, Narendran A, Gore L, Trippett TM, DeRenzo J, Foreman JK, Dunkel IJ. 2013. A phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high grade astrocytomas. Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, 31:117267.
• Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendren A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L, Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2013 Feb;60(2):230-6. PubMed PMID: 23024067
• Gore L, Zugmaier G, Handgretinger R, Locatelli F, Trippett TM, Rheingold SR, Bader P, Borkhardt A, Cooper TM, O’Brien MM, Zwann CM, Fischer A, Whitlock J, von Stackelberg A. 2013. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology, ASCO Annual Meeting Abstracts, 31: 108692.
• Locatelli F, Gore L, Mauz-Körholz C, Rosolen A, Landman-Parker J, Sanchez de Toledo J, Beishuizen A, Franklin ARK, Fasanmade A, Wang J, Fingert H, Labotka R, Neville K. 2013. Phase I/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: interim Phase 1 safety and pharmacokinetic data. 2013. Haematologica, 4138.
• Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb;31(1):115-25. PubMed PMID: 22415798
• von Stackelberg A, Zugmaier G, Handgretinger R, Locatelli F, Trippett TM, Rheingold SR, Bader P, Borkhardt A, Cooper TM, O’Brien MM, Zwaan CM, Fischer A, Whitlock J, Gore L. 2013. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL). Presented at the International Society of Paediatric Oncology (SIOP) Annual Meeting. Hong Kong. September 2013. Pediatric Blood and Cancer 2013;60(Suppl S3):29 [abstract #O-0105].
• Jayanthan A, Ruan Y, Hagerty M, Shah R, Truong T, Lewis VA, Boklan J, Trippett T, Gore L, Narendran A. 2013. In vitro growth inhibition, target modulation and drug synergy in pediatric leukemia by the novel proteasome inhibitor carfilzomib. Abstract #65734.
• Trippett T, Smith A, Neville K, Kieran M, Narendran A, Arceci R, Direnzo J, Gore L. 2013. Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors. Molecular Cancer Therapeutics (Supp).
• Jayanthan A, Ruan Y, Hagerty M, Shah R, Truong T, Lewis VA, Boklan J, Trippett T, Gore L, Narendran A. 2013. In vitro growth inhibition, target modulation and drug synergy in pediatric leukemia by the novel proteasome inhibitor carfilzomib. Blood 122:2673.
• Cooper TM, Malvar J, Cassar J, Eckroth E, Sposto R, Gaynon P, DuBois S, Chang B, Gore L, Macy M, August K, Thomson B, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown P. 2013. A Phase I Study of AC220 (quizartinib) in Combination with Cytarabine and Etoposide in Relapsed/refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Study. Blood 122:624.
• Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, Rheingold SR, Bader P, Bhojwani D, Cooper TM, DuBois SG, O'Brien MM, Zwaan CM, Holland C, Mergen N, Fischer A, Zhu M, Hijazi Y, Whitlock J, Gore L. 2013. A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Blood 122:70.
• Baker SD, Direnzo J, Trippett TM, Gore L, Narendran A, August KJ, Michael J. Absalon MJ, Boklan J, Pollard J, Magoon D, Sison EAR, and Brown P. 2013. Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS. Blood 122:2680.
• Neville KA, Rosolen A, Landman-Parker J, Aladjidi N, Beishuizen A, Daw S, Gore L, Franklin ARK, Fasanmade A, Wang J, Sachs J, Mauz-Koerholz C. 2013. Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm. Blood 122:4378.
• Karp JE, Gojo I, Pratz KW, Ghosh N, Gore SD, Showel MM, Levis M, Smith BD, Greer J, Herman JG, Gore L, Lee M-J, Lee S, Ordentlich P, Piekarz R, Trepel J. 2013. A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia. Blood 122:1427.
• Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug;99(8):1277-84. PubMed PMID: 25082785
• Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct;61(10):1792-7. PubMed PMID: 24962521
• Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1( ) leukemia. Am J Hematol. 2014 Sep;89(9):896-903. PubMed PMID: 24891015
• Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, Goldman S, Yalon M, Packer RJ, Korones DN, Smith A, Cohen K, Kuttesch J, Strother D, Baruchel S, Gammon J, Kowalski M, Bouffet E. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014 Nov;16(11):1554-9. PubMed PMID: 24847085
• Hoffman LM, Gore L. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol. 2014;4:63. PubMed PMID: 24744989
• Faulk K, Gore L, Cooper T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. Paediatr Drugs. 2014 Jun;16(3):213-27. PubMed PMID: 24639021
• Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 May;73(5):951-60. PubMed PMID: 24633809
• Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, Brachmann RK, Patnaik A. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs. 2014 Aug;32(4):653-60. PubMed PMID: 24604265
• Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. PubMed PMID: 24493827
• Hoffman LM, Gore L, Maloney KW. Pulmonary presentation of relapsed acute myeloid leukemia. J Pediatr Hematol Oncol. 2014 Apr;36(3):228-30. PubMed PMID: 23619108
• Gump JM, Donson AM, Birks DK, Amani VM, Rao KK, Griesinger AM, Kleinschmidt-DeMasters BK, Johnston JM, Anderson RC, Rosenfeld A, Handler M, Gore L, Foreman N, Hankinson TC. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun. 2015 May 21;3:30. PubMed PMID: 25990246
• Ashley D, Thomas D, Gore L, Carter R, Zalcberg JR, Otmar R, Savulescu J. Accepting risk in the acceleration of drug development for rare cancers. Lancet Oncol. 2015 Apr;16(4):e190-4. PubMed PMID: 25846099
• Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar;62(3):414-8. PubMed PMID: 25407157
• Burris H, Mellinghoff I, Maher E, Wen P, Beeram M, Touat M, Faris J, Azad N, Coughesy T, Gore L, Trent J, VonHoff D, Goldwasser M, Fan B, Wu B, Agresta S. 2015. The First Reported Results of AG-120, a First in Class Potent Inhibitor of the IDH1 Mutant Protein, in a Phase I Study of Patients with Advanced IDH1-Mutant Solid Tumors, Including Gliomas. Presented at the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston MA. November 2015.
• Cooper T, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang B, Gore L, August K, Pollard J, Dubois S, Silverman L, Oesterheld J, Gammon G, Magoon D, Annesley C, and Brown P. 2015. A phase I study of Quizartinib combined with Chemotherapy in Relapsed Childhood Leukemia: a TACL Study. Submitted to Clinical Cancer Research.
• von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. PubMed PMID: 27998223
• Awan FT, Gore L, Gao L, Sharma J, Lager J, Costa LJ. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. Br J Haematol. 2016 Oct;175(1):55-65. PubMed PMID: 27293194
• Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15;22(16):4014-22. PubMed PMID: 26920889
• Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 Jul;62:9-17. PubMed PMID: 27185573
• Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 Jan 20. [Epub ahead of print] PubMed PMID: 28105566
• Awan FT, Gore L, Gao L, Sharma J, Lager J, and Costa LJ. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia. In press, Clinical Cancer Research.
• Place AE, Pikman Y, Stevenson KE, Cooper TM, Gore L, Hijiya N, Loh ML, Pauly M, Sulis ML, Neuberg DS, Stegmaier K, Sallan SE, and Silverman LB. 2015. Phase I trial of the mTOR inhibitor Everolimus given in Combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic Leukemia. 2015. Presented at the Annual Meeting of the American Society of Hematology.
• Salzer W, Loh M, Devidas M, Hunger SP, Larsen EC, Gore L, Hilden J. Raetz E, Carroll W, Winick N, Burke M. 2015. Incidence of Allergic Reactions to Pegasparaginase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-cell lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group Studies AALL0232/AALL1131. Presented at the American Society of Hematology Annual Meeting. Blood, 1303.
• Shukla N, O'Brien MM, Silverman LB, Pauly M, Wetmore C, Loh ML, Whitlock JA, Brown P, Thomson B, Blakemore SJ, Daigle SR, Pimentel P, Waters NJ, Krivstov AV, Koche R, Armstrong S, Ho P, and Gore L. 2015. Preliminary Report of the Phase I study of the DOT1L Inhibitor Pinometostat (EPZ-5676) in Children with MLL-r Acute Leukemia: Safety, Exposure, and Evidence of Target Inhibition. 2015. Presented at the Annual meeting of the American Society of Hematology. Blood Abstract 3792.
• Lee Batlevi C, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorenson R, Ordentlich P, Cruickshank S, Kunkel L, Buglio D, Hernandez-Ilizaliturri F and Younes A. 2016. ENGAGE-501: Phase 2 study of Entinostat (SNDX-275) in Relapsed and Refractory Hodgkin Lymphoma. In press, Haematologica.
• Gore L, Farrar JE, Triche T, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Jones M, Martin L, Narendran A, Cuyugan L, Sekar S, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B. 2016. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Submitted, Clinical Cancer Research.
• Sender L, Wayne AS, Lee DW, Huynh V, Handgretinger R, Brown P, Gore L, Rosenthal J, Bot A, Rossi J, Jiang Y, Navale L, Stout S, Aycock J, Wiezorek J, Jain R. 2016. ZUMA-4: A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 (anti-CD19 Chimeric Antigen Receptor [CAR] T Cells) in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (R/R ALL). Presented at the PanPacific Lymphoma Conference. Koloa, HI. July 2016.
• Brown P, Kairalla J, Wang C, Dreyer Z, Salzer W, Sorenson M, Borowitz M, Carroll A, Heerema N, Rao K, Gore L, Devidas M, Carroll W, Winick N, Raetz E, Loh M, Hunger S, Hilden J. 2016. Addition of FLT3 inhibitor lestaurtinib to post-induction chemotherapy does not improve outcomes in MLL-rearranged infant acute lymphoblastic leukemia (ALL): AALL0631, a Children’s Oncology Group Study. Presented at the International Society of Pediatric Oncology Annual Meeting, Dublin, Ireland. Abstact number: SIOP6-0436.
• Huynh V, Wayne AS, Sender L, Lee DW, Handgretinger R, Pieters R, Michel G, Brown P, Gore L, Rosenthal J, Bot A, Rossi JM, Jiang Y, Navale L, Stout S, Aycock J, Wiezorek J, Jain R. 2016. ZUMA4: A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTEC19 AntiCD19 Chimeric Antigen Receptor (CAR) T Cells In Pediatric and Adolescent Patients with Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R ALL). Presented at the 41st Congress of the European Society for Medical Oncology (ESMO). Copenhagen, Denmark. October 2016.
• Razak A, Gore L, Britten C, Miller W, Uy G, Nichols G, Middleton S, Blotner S, Zhi J, Jukofsky L, Pierceall W, Higgins B, Chen L-C. 2016. A phase I dose escalation study of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous (IV) administration in patients with advanced solid tumors. Submitted to the AACR/NCI/EORTC Meeting on Molecular Targets and Cancer Therapeutics. Munich, Germany. October 2016.
• Shah B, Huynh V, Sender L, Lee D, Castro JE, Wierda W, Dietz AC, Schiller G, Kersten MJ, Handgretinger R, Brown P, Gore L, Gokbuget N, Rosenthal J, Sabatino M, Bot A, Rossi JM, Joang Y, Navale L, Stout S, Aycock J, Wiezorek J, Jain R, Wayne AS. 2016. High Rates of Minimal Residual Diseas-Negative (MRD-) Complete Responses (CR) in Adults and Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) with High Disease Burden (M3 marrow) Treated with KTE-C19 (anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials. Presented at the Annual American Society of Hematology Meeting. San Diego CA. December 2016.
• 120. Burke MJ, Brown P, Sposto R, Gore L, Chang BH, Cooper T, Dennis R, Baynon P, Hermiston M, Heym K, Huynh VT, Jeha S, Kaplan J, Laetsch T, Raetz E, Sulis ML, Ziegler D, Wayne A. Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Presented at the Annual Meeting of the American Society of Hematology. San Diego CA. December 2016.
• Sun W, Triche T Jr., Malvar J, Gaynon P, Sposto R, Yang X, Bittencourt H, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, Cooper TM, Liang G. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium. Blood. 2018 Jan 16. [Epub ahead of print] PubMed PMID: 29339403
• Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer. 2017 Dec 19. [Epub ahead of print] PubMed PMID: 29266189
• Mejstríková E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM, Zugmaier G, Gore L, von Stackelberg A, Locatelli F. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017 Dec 20;7(12):659. PubMed PMID: 29259173
• Maloney KW, Gore L. Agents in Development for Childhood Acute Lymphoblastic Leukemia. Paediatr Drugs. 2017 Nov 15. [Epub ahead of print] PubMed PMID: 29143289
• Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017 Nov;86:358-363. PubMed PMID: 29100190
• Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017;9:108. PubMed PMID: 29034009
• Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20;35(33):3737-3744. PubMed PMID: 28968170
• Gore L, Ivy SP, Balis FM, Rubin E, Thornton K, Donoghue M, Roberts S, Bruinooge S, Ersek J, Goodman N, Schenkel C, Reaman G. Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group. J Clin Oncol. 2017 Nov 20;35(33):3781-3787. PubMed PMID: 28968169
• Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2017 Sep 8. [Epub ahead of print] PubMed PMID: 28887726
• Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Kleinschmidt-DeMasters BK, Handler MH, Tan AC, Gore L, Virasami A, Gonzalez-Meljem JM, Jacques TS, Martinez-Barbera JP, Foreman NK, Hankinson TC. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. J Neuropathol Exp Neurol. 2017 Sep 1;76(9):779-788. PubMed PMID: 28859336
• Gore L. Drug development for rare cancers in children. Clin Adv Hematol Oncol. 2017 Jun;15(6):441-443. PubMed PMID: 28749903
• Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017 Nov;64(11). PubMed PMID: 28544128
• Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatr Blood Cancer. 2017 Aug;64(8). PubMed PMID: 28409853
• Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 Aug;35(4):471-477. PubMed PMID: 28105566
• O’Brien M, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yi J, Yuan C, Harris AC, Brown PA, Borowitz MJ, Militano O, Devidas M, Raetz EA, Gore L, Loh ML. 2019. A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children’s Oncology Group Protocol AALL1621. Oral Presentation at the Annual Meeting of the American Society of Hematology. Orlando, Florida. December 2019.
• Brown PA, Ji L, Xu X, Devidas M, Hogan L, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML. 2019. A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children’s Oncology Group Study AALL1331. Platform Late-Breaking Abstract Presentation at the Annual Meeting of the American Society of Hematology. Orlando, Florida. December 2019.
• Patterson B, Samis J, Gore L, Zwaan CM, Sacchi M, Hijiya N. 2019. Growth Rate and Endocrine Effects of Dasatinib Therapy: A Secondary Sub-Analysis of a Phase 2 Clinical Trial for Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Presented at the 29th Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD 2019). Seoul, South Korea. November 2019.
• Loh M, Rheingold S, Bhojwani D, Ji L, Xu X, Devidas M, Brown P, Gore L, Winick N, Carroll W, Raetz E, Hunger S. 2019. Determinants of survival after first relapse of childhood acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) Study. Presented at the 51st Congress of the International Society of Paediatric Oncology. Lyon, France. October 2019.
• Patterson BA, Samis J, Gore L, Zwaan CM, Sacchi M, Sy O, Hijiya N. 2019. Growth rate and endocrine effects of dasatinib therapy observed in a retrospective analysis of a Phase 2 clinical trial for pediatric patients with chronic myeloid leukemia in chronic phase (Cml-Cp). Oral Presentation at the European Society of Haematology Annual Meeting. Amsterdam, the Netherlands. June 2019.
• Rheingold SR, Raetz EA, Loh M, Gore L, Devidas M, Li J, Xu X, Brown P, Carroll W, Hunger SP, Bhojwani D. Prognostic Factors for Survival after Relapsed Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Study. Oral presentation at the American Society of Clinical Oncology Annual Meeting. Chicago, IL. June 2019.
• Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 Jan 22. [Epub ahead of print] PubMed PMID: 31969338
• Winters A, Gore L. Moving immunotherapy into the front line in ALL. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):209-217. PubMed PMID: 31808875
• Brown P, Zugmaier G, Gore L, Tuglus CA, von Stackelberg A. Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL. Br J Haematol. 2019 Dec 3. [Epub ahead of print] PubMed PMID: 31797346
• Abdul Razak AR, Miller WH Jr, Uy GL, Blotner S, Young AM, Higgins B, Chen LC, Gore L. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Invest New Drugs. 2019 Nov 16. [Epub ahead of print] PubMed PMID: 31734832
• Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720. PubMed PMID: 31300360
• Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019 May;104(5):986-992. PubMed PMID: 30545921
• Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. Br J Clin Pharmacol. 2019 Mar;85(3):530-539. PubMed PMID: 30428505
• Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019 Feb;94(2):257-265. PubMed PMID: 30394566
• Murphy L, Maloney K, Gore L, Blanchette E. Hypertension in Pediatric Acute Lymphoblastic Leukemia Patients: Prevalence, Impact, and Management Strategies. Integr Blood Press Control. 2022;15:1-10. PubMed PMID: 35082528
• O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 Jan 10;:JCO2101693. [Epub ahead of print] PubMed PMID: 35007127
• Slatnick LR, Jimeno A, Gore L, Macy ME. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today (Barc). 2021 Nov;57(11):677-688. PubMed PMID: 34821881
• Carraway HE, Sawalha Y, Gojo I, Lee MJ, Lee S, Tomita Y, Yuno A, Greer J, Smith BD, Pratz KW, Levis MJ, Gore SD, Ghosh N, Dezern A, Blackford AL, Baer MR, Gore L, Piekarz R, Trepel JB, Karp JE. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leuk Res. 2021 Nov;110:106707. PubMed PMID: 34563945
• Wright KD, Yao X, London WB, Kao PC, Gore L, Hunger S, Geyer R, Cohen KJ, Allen JC, Katzenstein HM, Smith A, Boklan J, Nazemi K, Trippett T, Karajannis M, Herzog C, Destefano J, Direnzo J, Pietrantonio J, Greenspan L, Cassidy D, Schissel D, Perentesis J, Basu M, Mizuno T, Vinks AA, Prabhu SP, Chi SN, Kieran MW. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021 Feb;68(2):e28787. PubMed PMID: 33140540
• Gore L, Keating AK. Eliminating disparities improves outcomes. Blood. 2021 Jan 28;137(4):439-441. PubMed PMID: 33507300
• Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 Jun;11(6):1424-1439. PubMed PMID: 33563661
• Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 May;35(5):1279-1290. PubMed PMID: 33623141
• Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 Mar 2;325(9):833-842. PubMed PMID: 33651090
• Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 May;35(5):1527. PubMed PMID: 33846544
• Hecht SL, Quach A, Gao D, Brazell A, Beltran G, Holbrook S, Gore L, Iguchi N, Malykhina A, Wilcox D, Cost NG. A prospective survey study of lower urinary tract dysfunction in childhood cancer survivors after vincristine and/or doxorubicin chemotherapy. Pediatr Blood Cancer. 2021 Oct;68(10):e29226. PubMed PMID: 34245214
• Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol. 2021 Nov 12;:JCO2101405. [Epub ahead of print] PubMed PMID: 34767461
• Advancing Pediatric Cancer Research: Impact and Implications of the RACE for Children Act
• Gore L. What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL. Best Pract Res Clin Haematol. 2022 Dec;35(4):101403. PubMed PMID: 36517120
• Pearson AD, Allen C, Fangusaro J, Hutter C, Witt O, Weiner S, Reaman G, Russo M, Bandopadhayay P, Ahsan S, Barone A, Barry E, de Rojas T, Fisher M, Fox E, Bender JG, Gore L, Hargrave D, Hawkins D, Kreider B, Langseth AJ, Lesa G, Ligas F, Marotti M, Marshall LV, Nasri K, Norga K, Nysom K, Pappo A, Rossato G, Scobie N, Smith M, Stieglitz E, Weigel B, Weinstein A, Viana R, Karres D, Vassal G. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 Dec;177:120-142. PubMed PMID: 36335782
• Burke MJ, Ziegler DS, Bautista F, Attarbaschi A, Gore L, Locatelli F, M O'Brien M, Pauly M, Kormany WN, Tian S, Morris CL, Baruchel A. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 Dec;69(12):e29999. PubMed PMID: 36215217
• Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, Attarbaschi A, Brown PA, Gardner RA, Gaynon PS, Hutchinson R, Huynh VT, Jeha S, Marcus L, Messinger Y, Schultz KR, Cassar J, Locatelli F, Zwaan CM, Wood BL, Sposto R, Gore L. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer. 2022 Nov;69(11):e29901. PubMed PMID: 35989458
• Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022 Sep 13;6(17):5222-5226. PubMed PMID: 35834728
• Lamble A, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard JD, Kovach AE, Wood BL, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2022 Apr 28. [Epub ahead of print] PubMed PMID: 35482927
• Pearson ADJ, Weiner SL, Adamson PC, Karres D, Reaman G, Rousseau R, Blanc P, Norga K, Skolnik J, Kearns P, Scobie N, Barry E, Marshall LV, Knox L, Caron H, Wariabharaj D, Pappo A, DuBois SG, Gore L, Kieran M, Weigel B, Fox E, Nysom K, de Rojas T, Vassal G. ACCELERATE - Five years accelerating cancer drug development for children and adolescents. Eur J Cancer. 2022 May;166:145-164. PubMed PMID: 35290915
• Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022 May 1;107(5):1205-1208. PubMed PMID: 35172563
• Brivio E, Baruchel A, Beishuizen A, Bourquin JP, Brown PA, Cooper T, Gore L, Kolb EA, Locatelli F, Maude SL, Mussai FJ, Vormoor-Bürger B, Vormoor J, von Stackelberg A, Zwaan CM. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. Eur J Cancer. 2022 Mar;164:1-17. PubMed PMID: 35121370
• Murphy L, Maloney K, Gore L, Blanchette E. Hypertension in Pediatric Acute Lymphoblastic Leukemia Patients: Prevalence, Impact, and Management Strategies. Integr Blood Press Control. 2022;15:1-10. PubMed PMID: 35082528
• O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 Mar 20;40(9):956-967. PubMed PMID: 35007127
• Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol. 2022 Mar 20;40(9):932-944. PubMed PMID: 34767461
• Lamble AJ, Moskop A, Pulsipher MA, Maude SL, Summers C, Annesley C, Baruchel A, Gore L, Amrolia P, Shah N. INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2023 Nov;29(11):674-684. PubMed PMID: 37689393
• Raetz EA, Teachey DT, Minard C, Liu X, Norris RE, Denic KZ, Reid J, Evensen NA, Gore L, Fox E, Loh ML, Weigel BJ, Carroll WL. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Pediatr Blood Cancer. 2023 Nov;70(11):e30609. PubMed PMID: 37553297
• Locatelli F, Shah B, Thomas T, Velasco K, Adedokun B, Aldoss I, Gore L, Hoelzer D, Bassan R, Park JH, Boissel N, Kantarjian H. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023 Oct;64(10):1615-1633. PubMed PMID: 37526512
• Raetz EA, Bhojwani D, Devidas M, Gore L, Rabin KR, Tasian SK, Teachey DT, Loh ML. Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30585. PubMed PMID: 37489549
• Pearson ADJ, Federico S, Gatz SA, Ortiz M, Lesa G, Scobie N, Gounaris I, Weiner SL, Weigel B, Unger TJ, Stewart E, Smith M, Slotkin EK, Reaman G, Pappo A, Nysom K, Norga K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Karres D, Kool M, Horner TJ, Henssen A, Heenen D, Hawkins DS, Gore L, Bender JG, Galluzzo S, Fox E, de Rojas T, Davies BR, Chakrabarti J, Carmichael J, Bradford D, Blanc P, Bernardi R, Benchetrit S, Akindele K, Vassal G. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2023 Sep;190:112950. PubMed PMID: 37441939
• Hawkins DS, Gore L. Children's Oncology Group's 2023 blueprint for research. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30569. PubMed PMID: 37433635
• Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, Borowitz MJ, Raetz EA, Carroll A, Heerema NA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Hunger SP, Loh ML. Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. J Clin Oncol. 2023 Sep 1;41(25):4118-4129. PubMed PMID: 37257143
• Moreno L, DuBois SG, Glade Bender J, Mauguen A, Bird N, Buenger V, Casanova M, Doz F, Fox E, Gore L, Hawkins DS, Izraeli S, Jones DTW, Kearns PR, Molenaar JJ, Nysom K, Pfister S, Reaman G, Smith M, Weigel B, Vassal G, Zwaan CM, Paoletti X, Iasonos A, Pearson ADJ. Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. J Clin Oncol. 2023 Jun 20;41(18):3408-3422. PubMed PMID: 37015036
• Queudeville M, Stein AS, Locatelli F, Ebinger M, Handgretinger R, Gökbuget N, Gore L, Zeng Y, Gokani P, Zugmaier G, Kantarjian HM. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2023 May 1;129(9):1384-1393. PubMed PMID: 36829303
• Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023 Feb 28;7(4):575-585. PubMed PMID: 35482927

Professional Memberships

• American Society of Hematology, Full Member
• American Association of Cancer Research, Full Member
• American Society of Clinical Oncology, Full Member
• Children’s Oncology Group, Member
• University of Colorado Cancer Center, Member
• American Society of Pediatric Hematology/Oncology, Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

Hospital Affiliation

• Children's Hospital Colorado
• University of Colorado Hospital

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Pediatric Hematology / Oncology, Board Certification (2001, 2017)
• Pediatrics, Board Certification (1996, 2003)
• PALS, Certificate (1993)
• BLS, Certificate (1994)
• American Board of Pediatrics, Board Certification (1996)
• American Board of Pediatrics - Hematology/Oncology Sub-Board, Board Certification (2000)

Conditions & Treatments

• Blood / Lymphatic System - Blood Disorders
• Blood / Lymphatic System
• Cancers
• Brain and Nervous System - Brain Tumors
• Cancers - Bone Cancer
• Cancers - Brain Cancer
• Cancers - Cancer Medicine
• Cancers - Chemotherapy
• Cancers - Leukemia (Adult Acute)
• Cancers - Leukemia (Adult Chronic)
• Cancers - Leukemia (Childhood)
• Cancers - Lung Cancer
• Cancers - Lymphoma
• Cancers - Pediatric Cancer
• Brain and Nervous System